Company: MDCXW
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001062993-25-008292
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-01
Form: DRS
Chunk 14
---
 not limited to, reduced disclosure obligations regarding executive compensation. We may continue to be a smaller reporting company as long as either (i) the market value of our common shares held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common shares held by non-affiliates is less than $700 million.

<div align='center'>- 5 -</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

<div align='center'>THE OFFERING</div>

This summary highlights information presented in greater detail elsewhere in this prospectus. This summary is not complete and does not contain all the information you should consider before investing in our securities. You should carefully read this entire prospectus before investing in our securities, including "Risk Factors" and our consolidated financial statements.

| Issuer                                        | Medicus Pharma Ltd.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Securities offered by the Selling Shareholder | 3,710,000 common shares, consisting of (i) 105,840 Commitment Shares and (ii) up to 3,604,160 common shares we may elect, in our discretion, to issue and sell to the Selling Shareholder under the SEPA from time to time.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Terms of the offering                         | The Selling Shareholder will determine when and how it will dispose of any common shares registered under this prospectus for resale.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Common shares to be outstanding               | 17,032,721 common shares, assuming the sale by us to the Selling Shareholder of a total of 3,604,160 common shares pursuant to the SEPA. The actual number of common shares issued will vary depending upon the actual sale prices under the SEPA.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Use of Proceeds                               | We will not receive any proceeds from the resale of common shares offered by this prospectus by the Selling Shareholder. However, we may receive up to $15,000,000 in aggregate gross proceeds under the SEPA from sales of common shares that we may elect to make to the Selling Shareholder pursuant to the SEPA, if any, from time to time in our discretion. We intend to use any net proceeds from sales pursuant to the SEPA to